

MarÃ-a Reig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5129924/publications.pdf>

Version: 2024-02-01

124
papers

15,961
citations

61984

43
h-index

17592

121
g-index

139
all docs

139
docs citations

139
times ranked

14524
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 593-604.	12.1	62
2	Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 283-292.e10.	4.4	94
3	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. <i>Liver Cancer</i> , 2022, 11, 75-84.	7.7	29
4	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2022, 76, 874-882.	3.7	17
5	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	3.7	1,495
6	Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study. <i>Lancet Oncology</i> , The, 2022, 23, 4-6.	10.7	3
7	HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. <i>Hepatology</i> , 2022, 76, 139-154.	7.3	42
8	HCC-neuroendocrine transition: Tumor plasticity under immunotherapy. <i>Gastroenterology</i> , 2022, , .	0.5	1
9	Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma progressing under first-line therapy (GOING trial), interim analysis and safety profile.. <i>Journal of Clinical Oncology</i> , 2022, 40, 428-428.	1.6	6
10	HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. <i>Journal of Hepatology</i> , 2022, 77, 128-139.	3.7	139
11	Reply to: "Correspondence on the BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update". <i>Journal of Hepatology</i> , 2022, 76, 1240-1241.	3.7	2
12	POLYETHYLENE-GLYCOL DRUG-ELUTING EMBOLIC MICROSPHERES LOADED WITH DOXORUBICIN FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: FEASIBILITY, SAFETY AND PHARMACOKINETIC STUDY. <i>Journal of Vascular and Interventional Radiology</i> , 2022, , .	0.5	2
13	Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria. <i>Hepatology</i> , 2022, 76, 1318-1328.	7.3	10
14	DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis. <i>Cancers</i> , 2022, 14, 2048.	3.7	5
15	THE COMPLEX MANAGEMENT OF HEPATOCELLULAR CARCINOMA: A MAJOR NEED OF EXPERTISE. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.3	0
16	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	3.9	11
17	Portal hypertension may influence the registration of hypointensity of small hepatocellular carcinoma in the hepatobiliary phase in gadoxetic acid MR. <i>Radiology and Oncology</i> , 2022, 56, 292-302.	1.7	0
18	Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment. <i>Gastrointestinal Disorders</i> , 2022, 4, 141-152.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver International, 2021, 41, 598-607.	3.9	13
20	Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. Cancers, 2021, 13, 426.	3.7	4
21	Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≥ 2 cm in cirrhotic patients. European Radiology, 2021, 31, 4794-4803.	4.5	8
22	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. European Journal of Radiology, 2021, 135, 109484.	2.6	20
23	Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity. Oncotarget, 2021, 12, 440-449.	1.8	1
24	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. Cell Death and Disease, 2021, 12, 555.	6.3	10
25	Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). Journal of Hepatology, 2021, 74, 1225-1233.	3.7	42
26	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Medicina Clínica (English Edition), 2021, 156, 463.e1-463.e30.	0.2	16
27	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 100260.	4.9	36
28	Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. Journal of Hepatology, 2021, 75, 1154-1163.	3.7	9
29	The TGF- β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. Cancers, 2021, 13, 3248.	3.7	37
30	Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs. United European Gastroenterology Journal, 2021, 9, 655-661.	3.8	2
31	Antioxidants Threaten Multikinase Inhibitor Efficacy against Liver Cancer by Blocking Mitochondrial Reactive Oxygen Species. Antioxidants, 2021, 10, 1336.	5.1	11
32	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. Liver Transplantation, 2021, 27, 1767-1778.	2.4	19
33	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. Journal of Hepatology, 2021, 75, 600-609.	3.7	127
34	Current pharmacological treatment of hepatocellular carcinoma. Current Opinion in Pharmacology, 2021, 60, 141-148.	3.5	12
35	Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas. European Journal of Medical Genetics, 2021, 64, 104313.	1.3	19
36	Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2021, 55, 263-270.	2.2	3

#	ARTICLE	IF	CITATIONS
37	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 90.	3.7	21
38	Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. <i>European Radiology</i> , 2020, 30, 186-194.	4.5	25
39	Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 710-719.	0.5	25
40	Reply to: "The reported "clear cut time association between interferon-free treatment and HCC" is anything but clear cut". <i>Journal of Hepatology</i> , 2020, 72, 1036-1037.	3.7	1
41	Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 192-192.	3.7	0
42	Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 719-737.	2.1	29
43	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. <i>Liver International</i> , 2020, 40, 2476-2488.	3.9	6
44	Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 3446.	3.7	19
45	Hepatic epithelioid hemangioendothelioma: An international multicenter study. <i>Digestive and Liver Disease</i> , 2020, 52, 1041-1046.	0.9	13
46	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020, 40, 1467-1476.	3.9	15
47	Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. <i>European Radiology</i> , 2020, 30, 6694-6701.	4.5	8
48	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 320-341.	3.7	165
49	Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. <i>Cancers</i> , 2020, 12, 332.	3.7	13
50	Insights into the success and failure of systemic therapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 617-630.	17.8	132
51	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3176-3184.	4.7	60
52	Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals. <i>Gastroenterology Y HepatologÃa (English Edition)</i> , 2019, 42, 502-511.	0.1	3
53	Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 482-491.	3.7	40
54	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019, 70, 874-884.	3.7	67

#	ARTICLE	IF	CITATIONS
55	Reply to: “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules” A response Journal of Hepatology, 2019, 71, 447-448.	3.7	0
56	Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents. Viruses, 2019, 11, 406.	3.3	11
57	SAT-482-Incidence of hepatocellular carcinoma after hepatitis C cure with DAA in a cohort of patients with advanced liver disease: Results from a prospective screening program. Journal of Hepatology, 2019, 70, e845.	3.7	2
58	Controversies in the management of hepatocellular carcinoma. JHEP Reports, 2019, 1, 17-29.	4.9	45
59	Should Patients With NAFLD/NASH Be Surveyed for HCC?. Transplantation, 2019, 103, 39-44.	1.0	52
60	New Systemic Treatments in Advanced Hepatocellular Carcinoma. Liver Transplantation, 2019, 25, 311-322.	2.4	21
61	Riesgo de recurrencia del carcinoma hepatocelular en pacientes tratados con antivirales libres de interferón. Gastroenterología Y Hepatología, 2019, 42, 502-511.	0.5	7
62	Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.. Journal of Clinical Oncology, 2019, 37, 327-327.	1.6	80
63	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncology, The, 2018, 19, 682-693.	10.7	285
64	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. Gastroenterología Y Hepatología, 2018, 41, 328-349.	0.5	71
65	New trials and results in systemic treatment of HCC. Journal of Hepatology, 2018, 69, 525-533.	3.7	49
66	Lenvatinib: can a non-inferiority trial change clinical practice?. Lancet, The, 2018, 391, 1123-1124.	13.7	12
67	Hepatocellular carcinoma. Lancet, The, 2018, 391, 1301-1314.	13.7	3,878
68	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. Hepatology, 2018, 67, 612-622.	7.3	55
69	Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. Oncotarget, 2018, 9, 16701-16717.	1.8	44
70	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterología Y Hepatología (English Edition), 2018, 41, 328-349.	0.1	7
71	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treatment Reviews, 2018, 68, 16-24.	7.7	124
72	Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success. Oncotarget, 2018, 9, 33741-33742.	1.8	1

#	ARTICLE	IF	CITATIONS
73	The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. Liver International, 2017, 37, 136-139.	3.9	31
74	Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. Journal of Hepatology, 2017, 66, 1114-1117.	3.7	26
75	Características clínicas del carcinoma hepatocelular en España. Comparación con el período 2008-2009 y análisis de las causas del diagnóstico fuera de cribado. Estudio de 686 casos en 73 centros. Medicina Clínica, 2017, 149, 61-71.	0.6	17
76	Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?. Seminars in Liver Disease, 2017, 37, 109-118.	3.6	73
77	Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. Medicina Clínica (English Edition), 2017, 149, 61-71.	0.2	4
78	Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial.. Journal of Clinical Oncology, 2017, 35, 4000-4000.	1.6	31
79	The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments. Oncotarget, 2017, 8, 106151-106152.	1.8	5
80	Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. World Journal of Gastroenterology, 2017, 23, 2448.	3.3	10
81	Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 117-131.	0.1	0
82	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. Journal of Hepatology, 2016, 65, 719-726.	3.7	883
83	Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opinion on Pharmacotherapy, 2016, 17, 1923-1936.	1.8	15
84	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. Medicina Clínica (English Edition), 2016, 146, 511.e1-511.e22.	0.2	2
85	Reply to “Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing”. Journal of Hepatology, 2016, 65, 864-865.	3.7	6
86	Treatment of Hepatocellular Carcinoma. Digestive Diseases, 2016, 34, 597-602.	1.9	72
87	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. Journal of Hepatology, 2016, 64, 1090-1098.	3.7	567
88	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology, 2016, 150, 835-853.	1.3	1,365
89	Pattern of tumor progression in liver cancer: The missing partner in trial design. Hepatology, 2015, 62, 674-676.	7.3	10
90	Reply. Hepatology, 2015, 62, 978-979.	7.3	0

#	ARTICLE	IF	CITATIONS
91	Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2015, 261, e105.	4.2	8
92	Does ramucirumab deserve a second chance for liver cancer?. <i>Lancet Oncology</i> , The, 2015, 16, 751-752.	10.7	3
93	Systemic Treatment: Expecting Further Success. <i>Digestive Diseases</i> , 2015, 33, 590-597.	1.9	1
94	Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. <i>Radiology</i> , 2015, 275, 698-707.	7.3	115
95	Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2cm. <i>Journal of Hepatology</i> , 2015, 62, 150-155.	3.7	46
96	Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. <i>Hepatology</i> , 2015, 61, 526-536.	7.3	286
97	Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST. <i>Seminars in Liver Disease</i> , 2014, 34, 444-455.	3.6	112
98	Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2014, 32, 554-563.	1.9	33
99	Systemic treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 921-935.	2.4	9
100	FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: Could a negative result be accepted as positive?. <i>Journal of Hepatology</i> , 2014, 61, 164-165.	3.7	3
101	Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. <i>Journal of Hepatology</i> , 2014, 61, 318-324.	3.7	203
102	Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design. <i>Hepatology</i> , 2013, 58, 2023-2031.	7.3	217
103	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. <i>European Journal of Cancer</i> , 2013, 49, 3412-3419.	2.8	218
104	Treatment of Hepatocellular Carcinoma with Radioembolization: Gathering Assumptions for Trial Design. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1197-1199.	0.5	2
105	If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection?. <i>Liver International</i> , 2013, 33, 1454-1456.	3.9	5
106	Evoluci3n natural y estratificaci3n del carcinoma hepatocelular. <i>Clinical Liver Disease</i> , 2013, 2, S333-S363.	2.1	0
107	Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 61, 1481-1487.	12.1	154
108	Management of HCC. <i>Journal of Hepatology</i> , 2012, 56, S75-S87.	3.7	509

#	ARTICLE	IF	CITATIONS
109	Natural history and staging for hepatocellular carcinoma. Clinical Liver Disease, 2012, 1, 183-185.	2.1	6
110	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. Journal of Hepatology, 2012, 56, 103-108.	3.7	142
111	Non-invasive diagnosis of hepatocellular carcinoma $\geq 1/2$ cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. Journal of Hepatology, 2012, 56, 1317-1323.	3.7	159
112	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. Journal of Hepatology, 2012, 56, 1330-1335.	3.7	436
113	The Search for an Effective Partner for Sorafenib: The Failure of Doxorubicin. Gastroenterology, 2011, 140, 1687-1688.	1.3	1
114	Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques. Hepatology, 2011, 54, 2238-2244.	7.3	101
115	Medical treatments: in association or alone, their roles and their future perspectives. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 420-421.	2.6	1
116	Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology, 2010, 51, 2020-2029.	7.3	268
117	Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects. Seminars in Liver Disease, 2010, 30, 061-074.	3.6	945
118	Treatment of early hepatocellular carcinoma: Towards personalized therapy. Digestive and Liver Disease, 2010, 42, S242-S248.	0.9	31
119	Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy. Annual Review of Medicine, 2010, 61, 317-328.	12.2	229
120	Cholangiocarcinoma in cirrhosis: Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology, 2009, 50, 791-798.	7.3	253
121	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma. Cancer, 2009, 115, 616-623.	4.1	403
122	New drugs for the treatment of hepatocellular carcinoma. Liver International, 2009, 29, 148-158.	3.9	22
123	α -Fetoprotein for Hepatocellular Carcinoma Diagnosis: The Demise of a Brilliant Star. Gastroenterology, 2009, 137, 26-29.	1.3	89
124	Sorafenib for Hepatocellular Carcinoma: Global Validation. Gastroenterology, 2009, 137, 1171-1173.	1.3	5